<DOC>
	<DOCNO>NCT00240539</DOCNO>
	<brief_summary>This study perform evaluate persistence anti-hepatitis B surface antigen ( HBs ) antibodies 16 , 17 , 18 , 19 20 year administration first dose study vaccine , Engerix-Bâ„¢ . No new subject recruit long-term follow-up study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination Newborns Mothers Who Were Seropositive Hepatitis B Envelope Antigen ( HBeAg ) &amp; Hepatitis B Surface Antigen ( HBsAg )</brief_title>
	<detailed_description>The primary study evaluate immunogenicity protective efficacy hepatitis B vaccine administer accord 0 , 1 , 2 , 12 month schedule newborns anti-hepatitis B envelope antigen positive ( HBeAg+ ) anti-hepatitis B surface antigen positive ( HBsAg+ ) mother . Results primary study show vaccine immunogenic protect neonate HBeAg positive mother hepatitis B chronic carriage . The present study carry evaluate anti-HBs persistence prevalence incidence hepatitis B marker ( HBsAg , anti-hepatitis B core antigen { anti-HBc } , HBeAg , Alanine aminotransferase/Aspartate aminotransferase { ALT/AST } ) , clinical significance HBsAg anti-HBc positive case observe long-term year 16-20 . No vaccine administer long term follow period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Subjects participate primary study . Written inform consent obtain subject .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis B</keyword>
</DOC>